Figure 7From: SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation statusTumor reduction of WSU-DLCL 2 xenograft treated with TW-37 compared with control. TW-37 was given at 40 mg/kg by i.v. injection for three consecutive days, tumors were measured consistently; number of animals per group = 5. P value ≤ 0.01.Back to article page